

Grifols publishes its 2018 Corporate Responsibility Report as part of its commitment to transparency

- *The report aims to offer Grifols' stakeholders a true and comprehensive overview of its social, environmental and economic performance in 2018, within the framework of the commitments assumed in the Social Corporate Responsibility Policy.*
- *In alignment with Global Reporting Initiative (GRI) information requirements and recommendations, the report was verified by an external independent firm and approved by Grifols' Board of Directors.*
- *Grifols' annual corporate governance report, financial statements and specific information on activities related to its foundations and Grifols' Academies are public documents, further underscoring the company's commitment to transparency.*

Barcelona (Spain), May 23, 2019.- Grifols (MCE:GRF, MCE:GRF.P and NASDAQ:GRFS), a global company that enhances the health and well-being of patients through the development of life-saving plasma-derived medicines, clinical diagnostics and pharmaceutical specialties for hospital use, today announced the publication of its 2018 Corporate Responsibility Report. The report highlights Grifols' firm commitment and pledge of transparency to its stakeholders, which include, among others, donors, patients, medical professionals, employees and society as a whole.

The information contained therein offers an in-depth view of Grifols' social engagement initiatives, ongoing training, commitment to inclusion and diversity, environmental actions, and respect for human rights and business ethics in compliance with Sustainability Reporting Standards of Global Reporting Initiative (GRI Standards).

Grifols' Corporate Responsibility Report covers the 2018 fiscal year, using a materiality analysis as its basis. The report was verified by an external independent company and approved by Grifols' Board of Directors on April 26, 2019.

Grifols aspires to continue to contribute toward economic, environmental and social progress on local, regional and global levels. The information relating to its 2018 performance is contextualized within the framework of the regions where it operates.

The report is available for download on Grifols' website: <https://www.grifols.com/en/investors>

GRIFOLS

Investor contact:

Investor Relations Department

inversores@grifols.com - investors@grifols.com

Phone number: +34 93 571 02 21

Media contact:

Raquel Lumbreras raquel_lumbreras@duomocomunicacion.com

Borja Gómez borja_gomez@duomocomunicacion.com

Duomo Comunicación Grifols Press Office

Phone number: +34 91 311 92 89 - +34 91 311 92 90

About Grifols

Grifols is a global healthcare company founded in Barcelona in 1940, committed to improving the health and well-being of people around the world. Its four divisions - Bioscience, Diagnostic, Hospital and Bio Supplies - develop, produce and market innovative solutions and services in more than 100 countries.

As pioneers in the field of the plasma science, Grifols is one of the largest plasma companies, with a growing network of donation centers worldwide. It develops this plasma into essential medicines used to treat rare, chronic and, at times, life-threatening conditions. As a recognized leader in transfusion medicine, Grifols also offers a comprehensive portfolio of solutions designed to enhance safety from donation through transfusion. And the company supplies tools, information and services that enable hospitals, pharmacies and healthcare professionals to efficiently deliver expert medical care.

Grifols, with more than 21,000 employees in 30 countries, is committed to a sustainable business model that sets the standard for continuous innovation, quality, safety and ethical leadership in the industry.

The company's class A shares are listed on the Spanish Stock Exchange, where they are part of the Ibex-35 (MCE:GRF). Grifols non-voting class B shares are listed on the Mercado Continuo (MCE:GRF.P) and on the U.S. NASDAQ through ADRs (NASDAQ:GRFS).

For more information, visit grifols.com